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Aims Congenital long QT syndromes (LQTSs) are associated with prolonged ventricular repolarization and sudden cardiac
death. Limitations to existing clinical therapeutic management strategies prompted us to develop a novel human
in vitro drug-evaluation system for LQTS type 2 (LQT2) that will complement the existing in vitro and in vivo models.
Methods and
results
Skin ﬁbroblasts from a patient with a KCNH2 G1681A mutation (encodes IKr potassium ion channel) were repro-
grammed to human induced pluripotent stem cells (hiPSCs), which were subsequently differentiated to functional
cardiomyocytes. Relative to controls (including the patient’s mother), multi-electrode array and patch-clamp electro-
physiology of LQT2–hiPSC cardiomyocytes showed prolonged ﬁeld/action potential duration. When LQT2–hiPSC
cardiomyocytes were exposed to E4031 (an IKr blocker), arrhythmias developed and these presented as early after
depolarizations (EADs) in the action potentials. In contrast to control cardiomyocytes, LQT2–hiPSC cardiomyocytes
also developed EADs when challenged with the clinically used stressor, isoprenaline. This effect was reversed by
b-blockers, propranolol, and nadolol, the latter being used for the patient’s therapy. Treatment of cardiomyocytes
with experimental potassium channel enhancers, nicorandil and PD118057, caused action potential shortening and
in some cases could abolish EADs. Notably, combined treatment with isoprenaline (enhancers/isoprenaline)
caused EADs, but this effect was reversed by nadolol.
Conclusions Findings from this paper demonstrate that patient LQT2–hiPSC cardiomyocytes respond appropriately to clinically
relevant pharmacology and will be a valuable human in vitro model for testing experimental drug combinations.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
The hereditary long QT syndromes (LQTSs) are characterized by
abnormal ventricular repolarization and are a recognized cause of
sudden cardiac death (SCD) syndrome.
1 Patients with LQTS carry
an increased risk of Torsades de Points [polymorphic ventricular
tachycardia (PMVT)], which can present with a host of clinical
manifestations varying from palpitations, syncope (fainting), and
seizures
2,3 to cardiac arrest and sudden death.
4 Long QT syn-
drome has been associated with over 500 different mutations in
at least 13 genes encoding cardiac ion channel proteins.
5 The esti-
mated genotype-to-phenotype correlation of 60–75% depends on
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6 In general,
mutations in the pore-forming regions have been linked to more
severe phenotypes, but large variations in penetrance are seen
even among family members carrying the same mutation.
7 The
incidence of LQTS is estimated to be 1:1000 individuals, 45% of
whom are diagnosed with LQTS type 2 (LQT2). LQT2 is caused
by mutations in the KCNH2 (also known as human Ether-a-go-go
Related Gene; HERG) gene, which forms the a-subunit of the
rapid-acting inward rectifying potassium (Ikr) channel.
8 Such
mutations have a dominant negative effect leading to reduced Ikr
function, which arises due to inappropriate protein maturation,
impaired protein trafﬁcking, or altered gating properties induced
in the wild-type channel.
9
Current treatments for LQT2 include the use of
b-adrenoreceptor antagonists (b-blockers), especially nadolol, a
non-selective class II anti-arrhythmic agent.
10 Even though
b-blockers are able to reduce the risk of cardiac episodes by
59%, 23% of LQT2 patients still experience cardiac episodes.
11
In these cases, and in patients otherwise felt to be at high risk of
a cardiac event,
12 surgery is required for implantation of a cardio-
verter deﬁbrillator (ICD). Left cardiac sympathetic denervation
13,14
may also be of value in patients where surges in sympathetic nerve
activity are causal in arrhythmogenesis. However, these invasive
procedures carry a risk of infection, can be traumatic to patients,
and are technically more demanding and liable to complication in
small children and infants. In vitro transgenic
15,16 and animal
models, such as cultured guinea-pig myocytes or arterially perfused
canine and rabbit left ventricular wedge preparations,
6 as well as in
vivo toxicity studies in monkeys or dogs have been used to develop
and safety screen novel pharmacological treatments for LQTS.
However, these models are not always predictive of drug activity
in human patients
8,10 and additional humanized test platforms
would be beneﬁcial.
Induced pluripotency involves reprogramming of somatic cells
into human induced pluripotent stem cells (hiPSCs) by introducing
genetic factors such as OCT4, SOX2, NANOG, and LIN28.
17 The
produced hiPSCs can be differentiated into a wide range of cell
types, including functional cardiomyocytes, and this has opened
new avenues for the generation of humanized in vitro models of
disease. A key goal is to produce a model of LQTS that responds
appropriately to clinically relevant pharmacology. This could
provide an opportunity to identify new routes of pharmacological
intervention and better tools to improve risk stratiﬁcation manage-
ment. Direct comparison of a particular patient genotype with
phenotype or drug response may also be possible. Therefore, to
explore these notions further, we generated patient-speciﬁc
hiPSCs from an individual suffering from LQT2 due to a KCNH2
mutation in the pore-forming region of Ikr. In addition, hiPSCs
were produced from the patient’s mother, who carries the same
mutation but is clinically asymptomatic for cardiac episodes.
Cardiomyocytes were derived from these hiPSCs, and from
genetically unrelated human pluripotent stem cells that did not
carry the mutation. Myocytes were analysed by electrophysiology,
with responses to existing and novel therapeutic drugs being
examined. The data presented for potassium channel and
b-adrenoreceptor modulators show the potential utility of patient-
speciﬁc hiPSC-derived cardiomyocytes in drug evaluation.
Methods
For details on hiPSCs, including generation, culture, differentiation, and
characterization, see Supplementary material online (Supplementary
Methods), and Dick et al.
18 and Anderson et al.
19
Mutation analysis of genomic DNA
To conﬁrm the presence of the KCNH2 G1681A mutation in patient-
speciﬁc ﬁbroblasts and derived hiPSCs, genomic DNA was extracted
from frozen cell pellets (QIAGEN DNeasy Blood and Tissue kit). Poly-
merase chain reaction (PCR) was performed using 25 mL reaction
mixture, which comprised Hotstar Taq polymerase (0.125 mL;
QIAGEN), 5 mM forward and reverse primers (F: GGAAGCTG
GATCGCTACTCA, R:GAAGTAGAGCGCCGTCACAT, 2.5 mL; Invi-
trogen), 10× buffer (2.5 mL; QIAGEN), 2.5 mM dNTPs (2.5 mL; Invi-
trogen) and 1 mL of genomic DNA diluted to 100 ng/mL. The PCR
conditions were 958C for 15 min, then 35 cycles (958C, 1 min; 558C,
30 s; 728C, 1 min) and a ﬁnal extension step at 728C for 5 min. Poly-
merase chain reaction products were electrophoresed on a 1.5%
agarose gel, puriﬁed (QIAGEN QIAquick Gel Extraction kit), and
sequenced using the reverse primer.
Analysis of KCNH2 1681 allele-speciﬁc
expression
RNA extraction from cells performed using the RNeasy Mini kit
(QIAGEN). Reverse transcription was performed using the First
Strand cDNA Synthesis kit (GE Healthcare), with 100 ng RNA.
Reverse transcription–PCR was performed as above, with 2 mLo f
cDNA, and addition of 2.5 mM MgCl2 (1 mL; QIAGEN) for detection
of the mutant allele. Primers used for the wild-type allele were F:
ACTTCAAGGGCTGGTTCCTC and R: ATGCAGGCTAGCCAG
TGCTC, and for the mutant allele were F: CTCTGGCTCTGAGGA
GCTGA and R: ATGCAGGCTAGCCAGTGCTT. Polymerase chain
reaction conditions were 958C for 15 min, then 37 cycles (958C,
1 min; 558C, 30 s; 728C, 1 min) with ﬁnal extension at 728C for 5 min.
Statistical analysis
Statistical analysis was performed using NCSS software for Windows
v7.1.15. The Kruskal–Wallis H test was used for analysis of non-
parametric independent data groups, and pair-wise comparisons
were performed using the Mann–Whitney’s U test. Tests were two-
tailed and signiﬁcance was assessed at a level of 0.05. Within-group
data are reported as mean values of experimental replicates + the
standard deviation of the mean to increase sensitivity towards biologi-
cal replicate experiments.
Results
Patient history and genetic proﬁle
The female LQT2 patient in this study presented at age of 15 years
with 11 episodes of syncope in 12 months with seizure on
occasions. She was a competitive swimmer, but had never experi-
enced episodes in relation to this activity. Episodes were nocturnal
and, whilst ECG monitored on the ward, were typically seen to
occur with arousal from sleep. This was indicative of LQT2,
since auditory stimuli causing arousal from sleep are described as
precipitants for ventricular arrhythmia in KCNH2 mutations.
3
A clinical episode of PMVT at rates of 230 bpm is shown in
Figure 1A, with full 12-lead ECGs in Supplementary material
Drug evaluation in LQT2 hiPSC cardiomyocytes 953online, Figure S1. The patient never experienced cardiac arrest or
needed cardiac resuscitation, and there was no family history of
sudden adult death syndrome. Whereas the patient’s echocardio-
gram, MRI, and signal-averaged electrocardiography were normal,
her QTc interval was up to 571 ms (Figure 1A; Supplementary
material online, Figure S1). Genetic screening showed that she
carried an LQT2-associated autosomal dominant point mutation
at KCNH2 (G1681A; Figure 1B). The mutation causes an alanine
to threonine substitution at position 561 of the encoded protein
(p.Ala561Thr) and is located in the pore-forming region of the
Ikr channel, at transmembrane segment S5 (Figure 1C),
20 and pre-
vents post-translational maturation of KCNH2.
21 With a QTc
.500 ms, a documented LQT2 gene mutation, and an adverse
clinical history, the patient was felt to be at signiﬁcant risk of a
future arrhythmic event and received a primary prevention
ICD.
12 She has so far remained arrhythmia free for 4 years on
b-blocker (nadolol) treatment. The patient’s mother (55 years)
is an asymptomatic carrier of the same mutation and is not
currently under treatment but does have a prolonged QTc of up
to 514 ms (Figure 1A and B). The father does not carry the
mutation and has a QTc of 445 ms (Figure 1A and B).
Derivation and characterization
of hiPSC lines
Human iPSCs were produced by reprogramming primary skin
ﬁbroblasts isolated from 4 mm punch biopsies taken from
the LQT2 patient (LQT2–hiPSC) and mother (MAT–hiPSC)
(Figure 2; Supplementary material online, Figure S2). HF–hiPSC
were produced from genetically unrelated hESC-derived ﬁbro-
blasts (Supplementary material online, Figure S2), while HUES7
cells were used as a hESC control.
22 Generation of hiPSCs was
by lentiviral delivery of human OCT4, SOX2, NANOG, and LIN28
(Figure 2; Supplementary material online, Figure S2).
18
Sequencing of genomic DNA showed that the G1681A
mutation in KCNH2 was present in LQT2–hiPSCs and MAT–
Figure 1 Clinical and genetic proﬁle of the LQT2 family. (A) Electrocardiogram of the LQT2 patient, showing prolonged QTc interval of up
to 571 ms (lead V5) and arrhythmic episode recorded during telemetry. Electrocardiograms of patient’s father (PAT; lead V5) and mother
(MAT; lead V5) are also presented. (B) Schematic diagram showing location of the KCNH2 gene on chromosome 7q36.1 and position of auto-
somal dominant point mutation in exon 7, at base 1681 of the coding sequence (G1681A). This missense mutation results in substitution of the
hydrophobic amino acid alanine (Ala), at position 561 of the protein, by the hydrophilic amino acid threonine (Thr; p.Ala561Thr). Results of
genomic DNA sequencing in ﬁbroblasts derived from hESCs (HF) and blood samples taken in hospital from LQT2 patient, mother, and father.
(C) Schematic representation of the Ikr potassium channel showing that KCNH2 p.Ala561Thr mutation is located in the S5 transmembrane
domain (black dot with red halo), which is involved in the pore-forming region of the channel.
E. Matsa et al. 954Figure 2 Derivation and characterization of LQT2 ﬁbroblasts and hiPSCs. (A) (i) Processing a 4 mm skin biopsy isolated from the LQT2
patient. (ii) Fibroblast outgrowths from digested skin sample, (iii) monolayer culture of LQT2 ﬁbroblasts (LQT2–Fib), (iv) hiPSC colony gen-
erated from LQT2–Fib following lentiviral transduction with OCT4, NANOG, SOX2, and LIN28, (v) LQT2–hiPSC colony at passage 1, (vi) mono-
layer culture of LQT2–hiPSCs at passage 15, grown in feeder-free conditions on Matrigel. Scale bars represent 100 mm. (B) Genomic
sequencing in LQT2–hiPSCs showing maintenance of the KCNH2 G1681A mutation. (C) Karyogram of LQT2–hiPSCs showing a normal
46XX karyotype, at passage 15. (D) RT–PCR analysis of OCT4, NANOG, SOX2, and LIN28 expression from endogenous (E) and lentiviral
(L) loci in LQT2–Fib, LQT2–hiPSCs, LQT2-hiPSC embryoid bodies. (E) Flow cytometry and (F) immunostaining for differentiation marker,
SSEA1, and pluripotency markers, TRA-1-81 and SSEA4, in LQT2–hiPSCs. (G) Immunostaining in LQT2-iPSC embryoid bodies for the
germ layer markers b-III-tubulin (ectoderm), a-fetoprotein (AFP; endoderm), and a-actinin (mesoderm). Scale bars in (E) and (F) represent
65 mm. (H) DNA methylation analysis for OCT4 and NANOG in LQT2–Fib, LQT2–hiPSC, and LQT2–hiPSC embryoid bodies, showing hypo-
methylation of hiPSCs relative to Fib and embryoid body samples.
Drug evaluation in LQT2 hiPSC cardiomyocytes 955hiPSC, but not in HF–hiPSC (Figure 2; Supplementary material
online, Figure S2), and HUES7 hESCs were conﬁrmed as
normal. Correspondingly, allele-speciﬁc RT–PCR showed
mutant KCNH2 G1681A transcripts were present in cells differ-
entiated from LQT2–hiPSCs and MAT–hiPSC, but not from
HF-hiPSC or HUES7 (see Supplementary material online, Figure
S2). Thus, mutation analysis in vitro was consistent with the
patient data.
All hiPSC lines had a normal karyotype (Figure 2) and displayed
population doubling rates similar to hESCs (see Supplementary
material online, Figure S2).
23 Flow cytometry and immunostaining
showed that hiPSCs had silenced the ﬁbroblast-speciﬁc marker
P4HB and the differentiation marker SSEA1, and had reactivated
the pluripotency markers TRA-1-81, SSEA4, OCT4, NANOG,
SOX2, LIN28, DNMT3B, REX1, KLF4, and cMYC (Figure 2; Sup-
plementary material online, Figure S3). Reverse transcription PCR
analysis conﬁrmed that the reprogramming factors OCT4,
NANOG, SOX2, and LIN28 were reactivated in the endogenous
loci, while lentiviral transgenes were silenced (Figure 2; Supplemen-
tary material online, Figure S2). Regulatory regions within the OCT4
and NANOG promoters acquired a hypomethylated state in hiPSCs,
relative to the originating ﬁbroblasts and hiPSC differentiated
progeny (Figure 2). EB differentiation from hiPSCs showed contri-
bution to the three embryonic germ layers; endoderm, ectoderm,
and mesoderm via expression of the markers b-III-tubulin,
a-fetoprotein, and cardiac a-actinin (Figures 2 and 3A). This con-
ﬁrmed that hiPSC lines were pluripotent.
Derivation and characterization
of cardiomyocytes
Differentiation of hiPSC lines to cardiomyocytes was induced via
embryoid bodies (EBs).
22 Spontaneously beating clusters
appeared from d11 of differentiation and occurred at similar efﬁ-
ciencies between the lines (not shown). Between d25–30,
beating clusters were mounted onto multi-electrode arrays
(MEAs) for electrophysiology analysis (Figure 3B and D). Alterna-
tively, they were dissociated into single cardiomyocytes, which
provided single cells for patch clamp analysis (Figure 3C) and
immunoﬂuorescence staining (Figure 3A). Cardiomyocytes from
patient and control lines expressed the cardiac markers,
a-actinin and Troponin-I, and showed characteristic cardiac
muscle striations (Figure 3A).
Patch clamp analysis of single cardiomyocytes demonstrated for-
mation of ventricular, atrial, and pacemaker subtypes, as deter-
mined by the morphology of action potentials generated
(Figure 3C)
24 and by the ratio of APD90/APD50 (Figure 3E). This
allowed comparison of action potential duration (APD) for differ-
ent cardiomyocyte subtypes derived from the hiPSC lines. Action
potential duration of ventricular and atrial myocytes from LQT2–
hiPSC was prolonged (881+204.8 and 870.2+165.3 ms,
respectively) relative to those from HF–hiPSC (386.2+138.7
and 467.1+75.8 ms) and hESCs (419.1+123.8 and 642+
35.5 ms) (Figure 4). However, MAT–hiPSC ventricular and atrial
cardiomyocytes had APDs of 704.45+57 ms and 667.6+156.0,
which were shorter than the values for the LQT2–hiPSC but
longer than for HF–hiPSC and hESC myocytes (Figure 4). Action
potential duration measured at 50 and 90% repolarization
showed similar prolongation in ventricular LQT2–hiPSC myocytes
(Figure 4). Pacemaker myocytes did not show signiﬁcant differences
between the lines (Figure 4).
To determine whether similar data could be extracted from
beating clusters, we used MEA analysis. This showed that the
ﬁeld potential duration (FPD) of LQT2–hiPSC myocytes was sig-
niﬁcantly prolonged (1026.5+203.6 ms; P ¼ 0.007; Figure 3B)
relative to those from MAT–hiPSC (658.3+115.9 ms) or controls
(HF–hiPSC, 644.3+133.4 ms; hESC, 859.5+75.5 ms).
Together, these data are in agreement with the long QTc inter-
vals seen in the clinical ECG data. However, they suggest that patch
clamp analysis of APDs is more sensitive because prolonged dur-
ations were detected in myocytes from LQT2–hiPSC and
MAT–hiPSC, whereas MEA analysis detected FPD prolongation
only in LQT2–hiPSC myocytes.
Sensitivity of LQT2 cardiac myocytes
to b-adrenoreceptor agonists and
antagonists
Speciﬁc genotype–phenotype correlations for triggers of life-
threatening events have been reported between the LQT syn-
dromes. Stimulation of the sympathetic nervous system appears to
be generally important; for LQT2 13 and 43% of episodes occur
with exercise and strong emotion, respectively. Auditory stimuli
have been linked to 26% of episodes in LQT2 patients.
25 Indeed,
stress testing of patients via sympathetic stimulation by the
b-adrenoreceptor agonist, isoprenaline, has been employed to
exacerbateanddiagnoseLQTS.
26Todeterminewhetherarrhythmic
events could be recapitulated in vitro, patient-speciﬁc and control
cardiomyocytes were treated with isoprenaline (Figure 5). In
beating clusters, isoprenaline caused a similar reduction in FPD of
control (20.4+11.8%; data pooled for MAT–hiPSC, HF–hiPSC,
and HUES7) and LQT2–hiPSC (24.1+12.7%; P . 0.05;
Figure 5A). However, LQT2–hiPSC myocytes dissociated to single
cells were more sensitive to isoprenaline treatment and showed a
signiﬁcantlylargerreduction(35.8+15.2%;P ¼ 0.018)inAPDrela-
tive to control cells (10.5+6.7%; Figure 5B). APD50 and APD90
values were affected similarly (Figure 5B and C). Subsequent treat-
ment with b-adrenoreceptor antagonists (or b-blockers), nadolol
and propranolol, resulted in a 30+19% increase in APD, in both
LQT2–hiPSC and control myocytes, and had a more pronounced
effect on APD50 than APD90 (Figure 5C).
In 25% of dissociated LQT2–hiPSC myocytes, treatment with
isoprenaline resulted in the appearance of electrophysiological
abnormalities, including early after depolarizations (EADs;
Figure 5D and E). In some cases, .50 consecutive beats were fol-
lowed by EADs. Such events were never observed in control
myocytes. Isoprenaline-induced arrhythmias in LQT2–hiPSC
myocytes were ameliorated by nadolol or propranolol. These in
vitro results are consistent with clinical observations, where
b-blockers are used to regulate cardiac episodes in LQT2
patients. Speciﬁcally, nadolol is currently the treatment of
choice for the LQT2 patient in this study, and propranolol has
been shown to suppress the inﬂuence of sympathetic stimulation
in LQT2 patients.
10,11,27
E. Matsa et al. 956Figure 3 Characterization of cardiac myocytes. (A) Immunostaining for cardiac troponin I (TrpI) and a-actinin in myocytes derived from
hESCs, HF–hiPSC, LQT2–hiPSC, and MAT–hiPSC, showing characteristic cardiac muscle striations. (B) Image of an LQT2–hiPSC beating
cluster mounted onto a multi-electrode array for electrophysiology analysis, and graph showing prolongation in QT interval and ﬁeld potential
duration in LQT2–hiPSC beaters relative to controls. (C) Image of a single LQT2–hiPSC beating cell undergoing patch-clamp analysis, and
action potential curves representing formation of ventricular, atrial, and pacemaker myocytes. (D) Schematic diagram of a multi-electrode
array trace, showing how results were analysed to calculate duration of the QT interval and ﬁeld potential duration. (E) Schematic diagram
of a patch-clamp trace, showing how results were analysed to calculate duration of the action potential and the action potential duration at
50 and 90% repolarization (APD50 and APD90, respectively). To determine the type of cardiac myocyte analysed, APD90/50 values ,1.4
designated ventricular cells, 1.4–1.7 designated pacemaker cells, and .1.7 designated atrial cells. Scale bars represent 130 mm.
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potassium channel blockers and openers
To further characterize the response of LQT2–hiPSC myocytes to
pharmacology, cells were treated with E4031 (Figure 6). This drug
causes blockade of the Ikr current through binding to the inner
cavity of the HERG channel in S6 or C-terminal domains.
28 In
beating cells from all hiPSC sources, E4031 caused prolongation
of FPD/APD (Figure 6A and B). This effect was particularly
evident in phases 2 and 3 of the action potential (Figure 6B) and
corresponds with the time when Ikr channels are most active.
29
E4031 treatment caused a 77.2% prolongation in the APD of
LQT2–hiPSC myocytes and 51.5% in control myocytes. Most
notably, E4031 treatment resulted in EADs in 30% of the
LQT2–hiPSC myocytes (Figure 6C), but this response was never
seen in controls.
The effect of two experimental potassium channel enhancers on
cardiomyocyte FPD/APD was evaluated (Figure 6D and E); nicoran-
dil, an IkATP channel opener,
30 and PD-118057, a type 2 Ikr channel
enhancer that attenuates channel closing.
28 In LQT2–hiPSC myo-
cytes, the APD was shortened by 18.6% with nicorandil and was
sufﬁcient to abolish spontaneously occurring EADs (Figure 6G).
Action potential duration was shortened by a further 29.5% (to
58.1%) with combined nicorandil and PD-118057 treatment
(Figure 6E). Treatment with PD-118057 alone abbreviated the
APD by 17.3% (Figure 6F). Both drugs exerted their effects in
phases 2 and 3 of the action potential, consistent with their mech-
anism of action (Figure 6E and F). This shows potassium channel
activators can normalize the prolonged repolarization of myocytes
carrying a mutation in the KCNH2 pore-forming region.
Next we evaluated whether potassium channel enhancers could
reverse the effect of the potassium channel blocker, E4031. Com-
bined treatment with E4031/nicorandil elicited 21.9 and 10.1%
APD shortening in control and LQT2–hiPSC myocytes (not
shown). Triple treatment with E4031, nicorandil, and PD-118057
resulted in further shortening of the APD by 8.9 and 2.4% in
control and LQT2–hiPSC myocytes (not shown). These data
suggest that the severe effect of potassium channel blockers
Figure 4 Electrophysiology analysis of cardiomyocytes. (A) Action potential curves showing prolongation in the action potential duration of
ventricular LQT2-hiPSC myocytes relative to controls. (B) Action potential curves showing prolonged action potential duration in atrial LQT2–
hiPSC myocytes relative to controls. (C) Box plots and (D) histograms demonstrating the distribution of action potential duration, and action
potential duration measured at 50 and 90% repolarization (APD50 and APD90, respectively) in ventricular, atrial, and pacemaker myocytes
derived from hESCs and hiPSCs. Histogram results are represented as mean+standard deviation.
E. Matsa et al. 958seen in LQT2–hiPSC cardiomyocytes are challenging to reverse by
potassium channel enhancers.
Finally, we evaluated the effect of the potassium channel enhan-
cers on myocytes in which b-adrenoreceptor pathways had been
stimulated or inhibited. As before, isoprenaline led to shortened
APD (Figures 5 and 6H). Irrespective of the source of hiPSCs, myo-
cytes treated with isoprenaline in combination with nicorandil and
PD-118057 developed EADs (Figure 6H). These effects could be
reversed by b-adrenoreceptor blockade with nadolol or propra-
nolol (Figure 6H). This observation suggests that patients treated
with potassium channel activators might run a higher risk of
cardiac arrhythmogenesis, for example, during exercise when
b-adrenoreceptor activation occurs.
Discussion
We isolated skin ﬁbroblasts from a patient carrying the autosomal-
dominant missense mutation KCNH2 G1681A, known to be
associated with LQTS type 2. The patient ﬁbroblasts were repro-
grammed to hiPSCs, which were differentiated to spontaneously
beating cardiomyocytes. The patient myocytes exhibited
expression of cardiac markers and electrophysiological properties
that conﬁrmed their functionality, as previously shown in hESC-
and hiPSC-derived cardiomyocytes.
31 Nevertheless, disease-
speciﬁc properties emerged in the LQT2–hiPSC myocytes, includ-
ing prolongation of the FPD/APD in beating clusters as well as in
atrial and ventricular cells, and increased sensitivity (appearance
of EADs) to stress induced by b-adrenoreceptor agonists.
Notably, although APD increases occurred in myocytes derived
from MAT–hiPSC, b-adrenoreceptor stimulation did not lead to
EADs. This is consistent with clinical data, which show that the
mother is an asymptomatic carrier of the KCNH2 G1681A
mutation who presents with a prolonged QTc but does not
require therapeutic intervention. This also supports the ﬁnding
that large variations in phenotype can occur in family members car-
rying the same mutation.
7,10 Why this happens remains unex-
plained, but may relate to additional polymorphisms throughout
the genome. Mutations in KCNQ1 or SCN5A, which underlie
LQT1 and LQT3, were not reported for the individuals in this
study and further analysis is needed to identify genetic and bio-
chemical differences between them. Clinically relevant b-blockers
restored the action potential of LQT2–hiPSC myocytes to
normal.
11 This included nadolol, which is the therapy used to regu-
late cardiac episodes in the LQT2 patient. Our ﬁndings also lend
support to the responses seen in hiPSC-derived LQT1 in vitro car-
diomyocyte models to b-adrenoreceptor agonists and antagon-
ists.
32 Our data also demonstrated that potassium channel
enhancers, such as nicorandil, are able to abolish EADs.
Figure 5 Sensitivity of cardiomyocytes to b-adrenoreceptor agonists and antagonists. (A) Multi-electrode array and (B) patch-clamp analysis
showing abbreviation of the ﬁeld potential duration and action potential duration with isoprenaline treatment (blue traces) relative to the spon-
taneous beating curves (black traces), as well as prolongation of the ﬁeld potential duration and action potential duration upon subsequent
addition of the b-blockers, nadolol (orange traces) or propranolol (green traces). Curves are representative of both control and LQT2–
hiPSC myocytes. (C) Graph showing increased sensitivity of LQT2–hiPSC myocytes to isoprenaline treatment relative to controls, and reversal
of isoprenaline effects by b-blockers in patient and control cells. (D–E) (i) Averaged and (ii) raw action potential curves of LQT2–hiPSC myo-
cytes showing isoprenaline-induced arrhythmogenesis (blue traces) and attenuation of this phenotype by nadolol (D, yellow trace) or propra-
nolol (E, green trace).
Drug evaluation in LQT2 hiPSC cardiomyocytes 959Long QT syndrome type 2–hiPSC myocytes were more sensi-
tive to treatment with the Ikr channel blocker, E4031. This suggests
that LQT2 patients could be more susceptible to arrythmogenesis
by drugs that are known to inhibit the Ikr current and hence have
the potential to prolong the QT interval, such as the recently with-
drawn cisapride, terfenadine, and lidoﬂazine.
33 Arrhythmic events
were not observed in control myocytes, but have previously
been reported in hESC-derived cardiomyocytes treated with high
doses of E4031.
34 Treatment with the experimental potassium
channel enhancers, nicorandil and PD-118057, subsequent to
E4031, had only a moderate effect on abbreviating the APD. In
the case of the IkATP activator, nicorandil, this was likely due to
administration of low drug doses, since high (10–20 mM) doses
have previously been shown to reverse HERG blockade in LQT2
canine models.
35 For PD-118057, the moderate effect was likely
due to differences in Ikr channel-binding sites and a different mech-
anism of action when compared with E4031.
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Potassium channel activators rescued prolonged action potential
of LQT2–hiPSC myocytes and in particular for the Ikr activator,
PD-118057, indicating that this class of drugs has a signiﬁcant
potential as an anti-arrhythmic agent against LQT2. Many com-
pounds have been identiﬁed to increase Ikr currents through
speciﬁc binding to different amino acid residues, and via several
different mechanisms.
36 Such speciﬁcity could be tailored to
patient treatment, depending on the mutation identiﬁed. In this
scenario, patients could be administered with an appropriate Ikr
channel activator to avoid using drugs that bind to protein sites
at which amino acids had been substituted by mutation. Develop-
ing multiple hiPSCs lines, each with a unique genotype, would allow
a degree of tailored drug evaluation to be carried out in vitro in
functional cardiomyocytes carrying LQT2, which is an avenue we
are investigating.
Administration of potassium channel openers in combination
with isoprenaline was pro-arrhythmic, likely due to excessive
shortening of the APD that elicited short-QT syndrome-like
responses.
11 Therefore, it will be important to monitor the
doses of potassium channel openers administered to patients. It
may be possible to combine these drugs with b-blocker treatment,
Figure 6 Sensitivity of cardiomyocytes to potassium channel blockers and openers. (A) Multi-electrode array and (B) patch-clamp analysis
showing elongation of the ﬁeld potential duration and action potential duration with E4031 treatment (purple traces) relative to the spon-
taneous beating curves (black traces). Curves are representative of both control and LQT2–hiPSC myocytes. (C) Action potential curves
of LQT2–hiPSC myocytes showing E4031-induced arrhythmogenesis. (D) Multi-electrode array and (E and F) patch-clamp analysis showing
shortening of the ﬁeld potential and action potential durations with nicorandil (red traces) and PD-118057 (pink traces) treatment. (G)
Action potential curves showing spontaneously occurring early after depolarizations (black trace) abolished by nicorandil treatment (red
trace). (H) Action potential traces of sequential drug treatment with isoprenaline, nadolol and PD-118057, resulting in the generation of
early after depolarizations due to excessive action potential duration shortening (pink trace). The phenotype was then attenuated with
nadolol treatment (yellow trace). (D–F) Curves of both control and LQT2–hiPSC myocytes.
E. Matsa et al. 960which was shown here to attenuate EADs caused by acute short-
ening of the APD. b-Blockers have also been shown to attenuate
nicorandil-induced tachycardia in canine in vivo models.
37 Combina-
torial treatment could beneﬁt cases where b-blocker treatment
worsens bradycardia leading to a 23% increased incidence of
cardiac events
13 or where arrhythmic events are caused during
stimulation of the parasympathetic nervous system during sleep
(22%).
6
Overall, these data support the notion that hiPSC-derived
cardiac myocytes can recapitulate the diseased phenotype of a
heritable cardiac condition, and are consistent with recent
reports of LQT1 and LQT2 (p.Ala614Val) hiPSC-based model-
ling.
32,38 However, there are important differences between our
work with KCNH2 G1681A (p.Ala561Thr) LQT2–hiPSCs when
compared with the KCNH2 p.Ala614Val mutation.
38 We identiﬁed
isoprenaline as an inducer of APD shortening and EAD develop-
ment, events not reported by Itzhaki et al.
38 and may relate to
the mutation location in the ion channel. We have also shown
that b-blockers used to manage cardiac electrophysiology in
LQT2 patients elicit stabilizing effects in myocytes derived from
LQT2–hiPSCs and that IKr channel activators, such as PD118057
represent a promising class of novel LQT2 anti-arrhythmic
agents. Finally, we showed combined treatment with potassium
channel enhancers and a b-adrenoreceptor stimulator led to
excessive shortening of the APD, perturbing electrophysiology.
This may indicate that potassium channel enhancers could be det-
rimental in patients experiencing stimulation of the sympathetic
nervous system (e.g. exercise) and will require careful investigation
before use.
In conclusion, we have developed a novel in vitro humanized
system that will be useful for evaluation of new treatments for
LQT2. Because the system relies on intact human cardiomyocytes
that display a diverse expression proﬁle of ion channels, it will
complement the high throughput analysis employed using aneu-
ploid cells (e.g. HEK293) transfected with a single channel gene.
Indeed, a key challenge will be to improve the throughput of the
hiPSC–cardiomyocyte system to allow a greater number of
drugs to be tested at pharmaceutical levels. Once this is achieved,
the human system will act as a comparator for myocytes isolated
from animals, where species differences may confound interpret-
ation. These activities will help rationalize datasets before drugs
are tested in complex, organized three-dimensional ex vivo (heart
slices, Langendorff system) or in vivo (intact animal or human
hearts) models. Notably, the techniques presented here have the
potential to inﬂuence future management and risk stratiﬁcation
of all forms of LQTS. They are also eminently translatable to
many other conditions that affect the heart (acquired LQTS,
cardiac failure or hypertrophy), as well as other heritable human
disorders.
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